Article

seattletimes.com on 2016-12-15 15:19

Eli Lilly’s sees strength in 2017, shares take off

Eli Lilly shares are up sharply after it laid out a better-than-expected 2017 forecast nearly a month after it had announced the failure of a key ...

Related news

Eli Lilly's sees strength in 2017, shares take off dothaneagle.com
Indianapolis
BVir Will Test Its Covid-19 Antibody With Eli Lilly’s, Sending Shares Up Again barrons.com
Vír
Eli Lilly’s Profit Dented by Higher Costs wsj.com
FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab Forbes
Eli Lilly’s New Compliance Chief on His Priorities6 min read wsj.com
Canada
Eli Lilly’s Antibody Trial Is Paused Over Potential Safety Concern The New York Times
Veterans Affairs
MEli Lilly’s therapy with solanezumab didn’t decelerate the illness mvtelegraph.com
Brigham City
Eli Lilly’s EFFIENT combination use patent found obvious jdsupra.com
California , United States , Switzerland
FHigh stakes: Eli Lilly’s hunt for an Alzheimer’s drug ft.com
South East Asia , China
FDA Panel Unanimously Recommends Eli Lilly’s Alzheimer’s Drug Forbes
BEli Lilly’s Earnings Raise Hopes for Pharmaceutical Stocks barrons.com
FEli Lilly & Co: US regulator delays decision on Eli Lilly’s Alzheimer’s drug ft.com
FEli Lilly & Co: Eli Lilly’s Alzheimer’s drug wins backing of US advisory panel ft.com
What Is Donanemab? Eli Lilly’s Alzheimer’s Drug Gets Delayed Decision From FDA Forbes
Indianapolis
A 3x Expected Rise In Mounjaro Sales Is Likely To Drive Eli Lilly’s Q1 Forbes
Poland , Krakow
IEli Lilly’s $123 billion market value drop: A strategic buying opportunity?invezz.com
FDA gives emergency clearance to Eli Lilly’s experimental COVID-19 antibody treatment New York Post
M$35 for insulin? What to know about Eli Lilly’s price slash for the diabetic medicine miamiherald.com
United States
IEli Lilly’s Tirzepatide approved in the EU days after US and UK approval invezz.com
United Kingdom , United States